Morphle Labs Raises $5 Mn To Automate Tissue, Blood Diagnostics

SUMMARY

The startup plans to deploy the freshly raised capital in scaling manufacturing for its flagship products RoboTome and MorphoLens

Morphle Labs claims to have filed for more than 80 patents

Founded in 2017, Morphle Labs leverages robotics, precision hardware, optics, and AI to build advanced technologies for automating tissue diagnostics

Cancer diagnosis startup Morphle Labs has raised $5 Mn (about INR 44.6 Cr) in its Series A funding round from Inflexor Ventures to enhance tech capabilities and expand global footprint.

The Bengaluru-based company, which also has operations in the US, is planning to deploy the freshly raised capital in scaling manufacturing for its flagship products RoboTome and MorphoLens. Additionally, the startup is also mulling to secure regulatory approvals and talent acquisition across engineering and research teams.

Founded in 2017 by Rohit Hiwale and Anchit Navelkar, Morphle Labs leverages robotics, precision hardware, optics, and AI to build advanced technologies for automating tissue diagnostics.

The company claims to have filed for more than 80 patents across robotics, optics, embedded systems, and imaging. The startup is currently expanding its commercial footprint in the US and Europe.

Its flagship product RoboTome automates the sectioning of tissue blocks into thin sections for microscope slides. This enables pathologists to get clean slides, resulting in more accurate and faster cancer diagnosis.

MorphoLens, on the other hand, is a digital slide imaging scanner for detailed tissue examination. This product is used by doctors and trained technicians to spot tiny cellular abnormalities

Morphle Labs’ third product, HemoLabs, is designed specifically for locating blood cells and platelet fragments for sorting and testing.

The startup joins a recent cohort of healthcare-focused deeptech companies raising early rounds to accelerate R&D and commercial deployment.

For instance, last month, biotech startup Helex raised $3.5 Mn in its seed funding to accelerate pre-clinical development of its lead programme, as part of which it is developing a drug to cure patients suffering from Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Similarly, Avammune Therapeutics recently raised $12 Mn to boost its IP portfolio and support clinical development of its lead candidate AVA-NP-695 (an ENPP1 inhibitor) and pre-clinical development of other pipeline molecules.